Disease staging of Alzheimer’s disease using a CSF-based biomarker model

A total of 426 participants from the Swedish BioFINDER-2 study (NCT03174938)¹⁹ with complete CSF data were included in the present study. Of these, 80 were cognitively unimpaired Aβ negative (CU−); 79 were cognitively unimpaired Aβ positive (CU+); 88 were diagnosed with MCI and were Aβ positive; 100 were diagnosed with AD dementia and were Aβ positive (ADD+); and 79 were assessed as non-AD patients (22 were Aβ positive). Demographic information is presented in Table 1 (see Supplementary Table 1 for demographic information by diagnostic groups). More detailed information about vascular risk factors and pathologies is provided in Supplementary Table 1, and a description of the diagnosis for non-AD patients can be found in Supplementary Table 2. Of these, 220 participants had longitudinal CSF data available (Supplementary Table 3).

CSF staging…